On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative reaction to the company's interim results released on August 27.

The company reported first-half revenue of USD 122 million, up 20.9% year-over-year, driven by molecule licensing and collaboration income rising to USD 113 million from USD 93.7 million. Research services and technology licensing fees also grew 23.8% to USD 9.4 million. However, net profit fell 11.16% to USD 64.85 million, as R&D costs surged from USD 17.96 million to USD 29.6 million and administrative expenses more than doubled from USD 7.36 million to USD 16.67 million, mainly due to increased headcount costs and litigation-related expenses. The persistent revenue-growth-without-profit-growth pattern has triggered consecutive sessions of selling pressure.

Within the Biotechnology sector, peers also traded lower: AKESO down 4.0%, INNOVENT BIO down 2.22%, BEONE MEDICINES down 1.3%, CANSINOBIO down 1.08%, while EVEREST MED bucked the trend with a 1.42% gain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)